PDCD1 and nasopharyngeal carcinoma: To overcome the bottleneck of immunotherapy based on PD-1 and PD-L1 and screen immunotherapy markers for advanced NPC patients, we analyzed the prognostic value of intratumoral and interstitial immune indicators for patients with nasopharyngeal cancer.